Genistein, a Dietary Isoflavone, Down-Regulates the MDM2 Oncogene at Both Transcriptional and Posttranslational Levels

Mao Li,1 Zhuo Zhang,1 Donald L. Hill,1,3 Xinbin Chen,2,3 Hui Wang,1,3 and Ruiwen Zhang1,3

1Department of Pharmacology and Toxicology, Division of Clinical Pharmacology; 2Department of Cell Biology; and 3Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama

Abstract

Although genistein has chemopreventive effects in several human malignancies, including cancers of the breast, colon, and prostate, the mechanisms of action are not fully understood. Herein we report novel mechanisms whereby genistein down-regulates the MDM2 oncogene, perhaps explaining some of its anticancer activities. In a dose- and time-dependent manner, genistein reduced MDM2 protein and mRNA levels in human cell lines of breast, colon, and prostate cancer; primary fibroblasts; and breast epithelial cells. The inhibitory effects were found at both transcriptional and posttranslational levels and were independent of tyrosine kinase pathways. We found that the NFAT transcription site in the region between \(-132\) and \(+33\) in the MDM2 P2 promoter was responsive to genistein. At the posttranslational level, genistein induced ubiquitination of MDM2, which led to its degradation. Additionally, genistein induced apoptosis and G2 arrest and inhibited proliferation in a variety of human cancer cell lines, regardless of p53 status. We further showed that MDM2 overexpression abrogated genistein-induced apoptosis \(\text{in vitro}\) and that genistein inhibited MDM2 expression and tumor growth in PC3 xenografts. In conclusion, genistein directly down-regulates the MDM2 oncogene, representing a novel mechanism of its action that may have implications for its chemopreventive and chemotherapeutic effects. (Cancer Res 2005; 65(18): 8200-8)

Introduction

Epidemiologic studies have shown that diet, which can vary substantially from one country to another, is one of the major factors in cancer etiology and may account for up to 35% of the differences in cancer rates among different countries (1). Consumption of soybeans reduces the risk for breast, prostate, stomach, colorectal, and lung cancers (2). For example, in societies where the consumption of isoflavone-containing soy foods is substantially higher than in the United States, the risk of breast cancer has been historically low (2). Increasing consumption of soy products is positively correlated to a reduction in breast cancer risk (3, 4). Isoflavones are present in high concentrations (1-5 mg/g) in soy products (5) and the American groundnut \(\text{(Apios americana; ref. 6)}\). In societies that consume soy-based foods as a regular part of their diet, an inverse relationship exists between isoflavone intake and the risk for several types of cancer (7, 8).

Two isoflavones, genistein (5,7,4′-trihydroxyisoflavone) and daidzein (7,4′-dihydroxyisoflavone), are likely predominant in the cancer preventive activity of soybeans. Genistein is now considered to be the primary anticancer component of soybeans; its \(\text{in vitro}\) and/or \(\text{in vivo}\) activities include the antagonism of estrogen, inhibition of protein tyrosine phosphorylation, suppression of angiogenesis, inhibition of hydrogen peroxide formation induced by tumor promoters, inhibition of topoisomerasers, induction of apoptosis and cell differentiation, scavenging of free radicals, and inhibition of carcinogenesis and tumor promotion (2, 9–13).

In animal models of mammary gland, liver, colon, skin, prostate, and stomach carcinogenesis, soy consumption reduces the development of cancers (7). Dietary genistein reduces the multiplicity of mammary and prostate tumors that develop in carcinogen-dosed murine models (14, 15). In mammary tumors, the protective effects are seen for both estrogen-dependent and -independent tumors. Dietary genistein also reduces the incidence of aberrant crypts and colon cancer in carcinogen-dosed rats (16). In addition to its cancer preventive effects, genistein has a role in cancer therapy (17, 18). The mechanisms of action for its chemopreventive and chemotherapeutic effects, however, are not fully understood.

Considering the inhibitory effects of genistein on carcinogenesis and tumor growth, its potential effects on the regulation of oncogenes should be investigated. The mouse double minute 2 (MDM2) oncoprotein is a negative regulator of tumor suppressor p53, blocking p53 transcriptional activity and promoting its proteasome-mediated degradation (19). Nevertheless, the p53-independent effects of MDM2 have attracted increasing attention in recent years. MDM2 interacts with various cellular proteins, including p19/14\(^{\text{ARF}}\), E2F1, p300, ribosomal L5/L11/L23 proteins, and p73. The MDM2 oncoprotein is overexpressed in many human malignancies, and high MDM2 levels are associated with poor clinical prognosis (19). Antisense inhibition of MDM2 expression results in substantial \(\text{in vitro}\) and \(\text{in vivo}\) antitumor activities in breast, colon, and prostate cancer models (20–24). The present study was designed to test our hypothesis that genistein may down-regulate the expression of the MDM2 oncogene.

Our results indicate that genistein has a novel mechanism of action, whereby it specifically down-regulates MDM2 at both transcriptional and posttranslational levels. At the transcriptional level, the NFAT site in the MDM2 promoter is important for the effects of genistein. At the posttranslational level, genistein induces MDM2 ubiquitination, which is relevant to down-regulation of the MDM2 protein. We further show the importance of this MDM2 inhibitory effect relative to the antitumor activities of genistein \(\text{in vitro}\) and \(\text{in vivo}\). We also provide evidence of genistein-mediated, p53-independent up-regulation of the tumor suppressor p21\(^{\text{WAF1/CIP1}}\) at the posttranslational level, which may be associated with MDM2 down-regulation.
Materials and Methods

Plasmids and reagents. Human full-length, deleted, and ETSa, AP1, and ETSa-AP1 double-mutated P2 MDM2 promoter reporters were kind gifts from Dr. J.P. Blaydes (Southampton General Hospital, United Kingdom). P2 promoter reporters with MEF2, NFAT, and ETSa-AP1-NFAT triple mutations were generated by proofreading PCR and verified by sequencing. The vectors for wild-type MDM2 and mutant MDM2 (C464A) without E3 ligase activity were kindly provided by Dr. J. Chen (Moffitt Cancer Center) and Dr. C.G. Maki (University of Chicago). The human MDM2 cDNA insert was digested with BamHI and XhoI and subcloned into the same sites of pcDNA3. To construct short interfering RNA (siRNA) expression plasmids under the control of the U6 promoter, selected oligonucleotides were cloned into pBabe-U6 at BamHI and XhoI sites for expression of siRNA in vivo. One pair of siRNA oligonucleotides from p53 were synthesized and cloned into pBabe-U6. The target sequence of the oligonucleotides for p53 knockdown (derived from the p53 gene) was 5′-GACTCCAGTGGAATCTCACC-3′. Genistein was purchased from Sigma (St. Louis, MO).

Cell lines and cell culture. HCT116 (p53+/+) and HCT116 (p53−/−) cells were kindly provided by Dr. B. Vogelstein (Johns Hopkins) and maintained in McCoy’s 5A medium. Human primary fibroblasts (IMR90) were gifts from Dr. S. Lee (Harvard; refs. 25, 26). MCF10A, MCF-7, and PC3 cells were obtained from Dr. J.P. Blaydes (Southampton General Hospital, United Kingdom). P2 promoter activity were kindly provided by Dr. J. Chen (Moffitt Cancer Center) and Dr. C.G. Maki (University of Chicago). The human MDM2 cDNA insert was digested with BamHI and XhoI and subcloned into the same sites of pcDNA3. To construct short interfering RNA (siRNA) expression plasmids under the control of the U6 promoter, selected oligonucleotides were cloned into pBabe-U6 at BamHI and XhoI sites for expression of siRNA in vivo. One pair of siRNA oligonucleotides from p53 were synthesized and cloned into pBabe-U6. The target sequence of the oligonucleotides for p53 knockdown (derived from the p53 gene) was 5′-GACTCCAGTGGAATCTCACC-3′. Genistein was purchased from Sigma (St. Louis, MO).

Reverse transcription-PCR. Total RNA was extracted using the Trizol reagent from Invitrogen (Carlsbad, CA), quantified by UV spectrophotometry, and used to create cDNA with the SuperScript reverse transcription-reagent from Invitrogen (Carlsbad, CA), quantified by UV spectrophotometry.

Luciferase assay. Cells were cotransfected with full-length, deleted, or mutated human MDM2 P2 promoter vectors with Renilla luciferase reporter (as internal control; Promega, Madison, WI) for 12 hours followed by incubation with genistein for 24 hours. The luciferase activity of the reporter (as internal control; Promega, Madison, WI) for 12 hours followed by incubation with genistein for 24 hours. The luciferase activity of the reporter (as internal control; Promega, Madison, WI) for 12 hours followed by incubation with genistein for 24 hours. The luciferase activity of the reporter (as internal control; Promega, Madison, WI) for 12 hours followed by incubation with genistein for 24 hours. The luciferase activity of the reporter (as internal control; Promega, Madison, WI) for 12 hours followed by incubation with genistein for 24 hours.

results

Genistein inhibits MDM2 expression in human cancer and primary cell lines, regardless of p53 status. The effects of genistein on MDM2 expression were first analyzed in cancer cells containing wild-type p53. HCT116 and MCF-7 cells were treated with various concentrations of genistein for 24 hours or with 50 μmol/L genistein for varying times. MDM2 protein levels were decreased in a time- and concentration-dependent manner (Fig. 1A and B). Most likely as a result of the inhibition of MDM2, the p53 protein level was elevated (Fig. 1A and B). The expression level of p21Waf1/CIP1, a p53 target gene, was also elevated (Fig. 1A and B). To test whether the inhibitory effects of genistein on MDM2 require p53, HCT116 (p53−/−), MCF-7 (p53KD; p53 was knocked down by

Figure 1. Effects of genistein on MDM2 expression in human cancer cells. A, HCT116 cells with wild-type (p53+/+) or without p53 (p53KD), MCF-7 cells with wild-type (p53+/+) or without p53 (p53KD), and PC3 cells (p53KD) were treated with various concentrations of genistein for 24 hours, and the target proteins (MDM2, p53, p21, and β-actin) were detected by immunoblotting with specific antibodies. B, these same cell lines were treated with 50 μmol/L of genistein for various times, and the target proteins were detected by immunoblotting. KD, knockdown.
siRNA), and PC3 (p53null) cells were treated with genistein as above. In a dose- and time-dependent manner, MDM2 expression was inhibited in all the cell lines (Fig. 1A and B), p21Waf1/CIP1 expression levels were elevated (Fig. 1A and B), independent of the expression of p53, indicating that genistein may inhibit the p21 regulatory function of MDM2, as was previously noted when MDM2 antisense oligonucleotides were used (21–24). The modulatory effects of genistein on MDM2 in the presence of p53 were further confirmed in primary human fibroblasts (IMR90) and human breast epithelial cells (MCF10A), which were treated with various concentrations of genistein as above. MDM2 was down-regulated by genistein dose dependently (Fig. 2). To test whether this effect depends on the presence of p53, a p53 knockdown siRNA plasmid was transfected in IMR90 cells. Later (24 hours), these cells were treated with various concentrations of genistein for 24 hours; MDM2 expression was still shown to be inhibited by genistein (Fig. 2).

**MDM2 transcription is repressed by genistein.** To address the possible underlying mechanisms of MDM2 inhibition by genistein at the transcriptional level, HCT116 (p53−/−), MCF-7 (p53KD), and PC3 (p53null) cells were treated with various concentrations of genistein for 24 hours, and the MDM2 mRNA expression levels were determined by RT-PCR. As shown in Fig. 3A, MDM2 mRNA levels were decreased by genistein in all three cell lines in a concentration-dependent manner. To confirm these results, a human MDM2-P2 promoter reporter (Luc01) was transfected into PC3 cells that were subsequently treated with genistein (Fig. 3B1). The luciferase activity of the MDM2 reporter was decreased 70% by genistein (50 μmol/L); there were no apparent changes in the cells transfected with the corresponding empty vector reporter (Fig. 3B2). We next identified the genistein-responsive element on the MDM2-P2 promoter. The reporter vectors used in this

![Figure 2. Down-regulation of MDM2 by genistein in human primary cells. IMR90-EEA and MCF10A cells were treated with various concentrations of genistein as above. Target proteins were detected by immunoblotting. To test whether this effect depends on p53 or not, IMR90-EEA cells were transfected with p53 knockdown siRNA plasmids followed by the treatment with various concentrations of genistein for additional 24 hours. Target proteins were examined as above.](image)

![Figure 3. Effects of genistein on MDM2 expression at the transcriptional level, independent of p53. A, HCT 116 cells without p53 (p53−/−), PC3 cells (p53null), and MCF-7 cells without p53 (p53KD) were treated with various concentrations of genistein for 24 hours followed by the extraction of total RNA. MDM2 mRNA was coamplified with β-actin mRNA. B1, comparison of structures of deleted MDM2 promoters with the full-length promoter. B2, PC3 cells were transfected with the MDM2 reporter construct (Luc01) or corresponding empty vector (pGL3-Basic) for 12 hours followed by incubation with various concentrations of genistein for an additional 24 hours, before luciferase activities were quantified. Columns, means of duplicate assays; bars, ±SD. B3, PC3 cells were transfected with MDM2 deletion reporters (Luc01, Luc03, Luc06, and Luc23) in parallel with the full-length reporter (Luc01) for 12 hours followed by incubation with 0 or 50 μmol/L of genistein for an additional 24 hours. The luciferase activity of each reporter treated with 50 μmol/L of genistein is a percentage of that obtained for the control (no genistein). Columns, means of duplicate assays; bars, ±SD. B4, PC3 cells were transfected with MDM2 mutation reporters (Luc01ΔMEF2, Luc01ΔETSa, Luc01ΔAP1, and Luc01ΔNFAT) in parallel with full-length reporter (Luc01) for 12 hours followed by the incubation with 0 or 50 μmol/L of genistein for an additional 24 hours. The luciferase activity of each reporter treated with 50 μmol/L of genistein is a percentage of that obtained for the control (no genistein). Columns, means of duplicate assays; bars, ±SD.](image)
Figure 4. p53-independent effects of genistein on MDM2 expression at the posttranslational level. MDM2 (A1) or p21 (A2) protein levels in 50 μmol/L of genistein- or DMSO-treated PC3 cells were detected by immunoblotting at different time points after the protein synthesis inhibitor cycloheximide (10 μg/mL) was added. Graphs (bottom) show quantification of the immunoblotting data. Similar experiments were done at least three times and produced similar results. B1, PC3 cells were transfected with MDM2 and ubiquitin, treated with genistein while prolonging the p21 Waf1/CIP1 protein half-life (Fig. 4). Genistein increased the degradation rate of the MDM2 protein (Fig. 4). The changes in MDM2 expression were detected by immunoblotting.

To confirm the results, other P2 promoters with ETS, AP1, MEF2, and NFAT mutations, respectively, were transfected into PC3 cells, which were then treated as above. The ubiquitinated MDM2 in cell lysates was isolated using an MDM2 antibody and detected by a ubiquitin antibody (Fig. 4). This ubiquitinated MDM2 showed that the shortest segment (−132 to +33; Luc 03) still retained the response to genistein (Fig. 3B). There are several transcription factor response sites between −132 and +33 in the MDM2 P2 promoter, including sites for ETS, AP1, MEF2, and NFAT. ETS-AP1 is responsible for the activation of the promoter by growth factors dependent on the ras/raf/mitogen-activated protein kinase (MAPK) kinase (MEK)/MAPK pathways (27).

To determine which site is involved in the effects of genistein, four P2-luciferase vectors with ETSa, AP1, MEF2, and NFAT mutations, respectively, were transfected into PC3 cells, which were then treated with genistein. The NFAT mutation abrogated the response of the P2 promoter to genistein; the other three mutant vectors retained the capacity to respond (Fig. 3B). To confirm the results, other P2 promoters with a double mutation (ΔAP1-ETSa) or triple mutation (ΔAP1-ETSa-NFAT) were tested following a similar protocol. The ETSa-AP1 mutation had no effect on the response of the P2 promoter to genistein. In contrast, mutation of NFAT in addition to the ETSa-AP1 mutation reduced the response (Fig. 3B).

Genistein promotes degradation of the MDM2 protein, independent of p53. The effects of genistein on MDM2 regulation were also determined at the posttranscriptional level. In PC3 cells, genistein increased the degradation rate of the MDM2 protein (Fig. 4A) while prolonging the p21\textsuperscript{WAF1/CIP1} protein half-life (Fig. 4A). To elucidate the underlying mechanisms, PC3 cells were transfected with MDM2 and ubiquitin, treated with genistein for 24 hours, and then exposed to the proteasome inhibitor MG132 (25 μmol/L) for an additional 6 hours. Genistein increased the ubiquitination of MDM2 (Fig. 4B1). This ubiquitinated MDM2 protein was also detected by immunoprecipitation in a separate study in which PC3 cells were transfected with ubiquitin and treated as above. The ubiquitinated MDM2 in cell lysates was isolated using an MDM2 antibody and detected by a ubiquitin antibody (Fig. 4B2). This increase is due to increased autoubiquitination; an MDM2 mutant (C464A) without ubiquitin E3 ligase activity (C464A) was resistant to the inhibitory effects of genistein (Fig. 4B3) and was degraded more slowly than the wild-type protein in the presence of genistein (Fig. 4B4).

Inhibitory effects of genistein on tyrosine kinases are not required for the down-regulation of MDM2. Genistein is a potent and pan-tyrosine kinase inhibitor (2), and the MDM2 protein is subject to posttranslational modifications, including phosphorylation, which affects its localization, activities, and stability (28). To determine whether the tyrosine kinase inhibitor activity is involved in the down-regulation of MDM2 by genistein, PC3 cells were pretreated with genistein for 24 hours, then exposed to epidermal growth factor (EGF) for an additional hour. Genistein induced dephosphorylation of extracellular signal-regulated kinase, which was reversed by exposure to EGF (Fig. 5A1). However, down-regulation of MDM2 was not affected by EGF, suggesting that tyrosine kinase inhibition is likely not responsible for the inhibition of MDM2 by genistein (Fig. 5A1). This observation was confirmed using an inhibitor of protein tyrosine phosphatase. The inhibitory effects of genistein were not reversed by pretreatment of PC3 cells with Na\textsubscript{2}VO\textsubscript{4} for 3 hours before exposure of the cells to genistein for 24 hours (Fig. 5A2). In a separate experiment, prior inhibition of...
tyrosine kinases by lavendustin did not prevent the down-regulation of MDM2 by genistein (Fig. 5B1). HCT116 (p53\(^{-/-}\)) cells were pretreated with lavendustin (inhibitor of protein kinase) for 3 hours followed by incubation with genistein for 24 hours (Fig. 5B1). Another protein tyrosine kinase inhibitor, AG18, which was added to PC3 cells 3 hours before genistein treatment, was also unable to block the inhibitory effects of genistein (Fig. 5B2).

**Genistein has antitumor effects on apoptosis, cell cycle distribution, and cell proliferation, regardless of cellular p53 status.** In a dose-dependent manner, genistein induced apoptosis (Fig. 6A), inhibited cell proliferation (Fig. 6B), and caused \(G_2-M\) phase cell cycle arrest (Fig. 6C) in human cancer cells with wild-type p53 (HCT116 and MCF-7) and in cells without p53 expression (HCT116 (p53\(^{-/-}\)), MCF-7 (p53KD), and PC3 (p53\(^{null}\)).

**In vitro antitumor activities of genistein are associated with its capacity to down-regulate MDM2.** As illustrated in Fig. 7A, the elevation of p21 protein induced by genistein was inhibited by MDM2 overexpression in PC3 cells; the genistein-induced apoptotic effect was also eliminated by MDM2 overexpression (Fig. 7B). Additionally, MDM2-overexpressing PC3 cells were less responsive to the antiproliferative effects of genistein, as measured by BrdUrd incorporation (Fig. 7C). Moreover, overexpression of MDM2 facilitated the survival of PC3 cells, as shown by clonogenic assays (Fig. 7D1 and D2).

**In vivo MDM2 inhibition by genistein shows dose-dependent antitumor activity and chemosensitization, independent of p53.** The antitumor activity of genistein was further shown in the PC3 xenograft model, which is p53 null (Fig. 7E1). In this model, genistein also increased the therapeutic effectiveness of gemcitabine (Fig. 7E1). The protein levels of MDM2 were decreased by genistein in a dose-dependent manner, resulting in elevation of p21 (Fig. 7E2).

**Discussion**

Genistein, a naturally occurring isoflavone, is of interest because of its potent chemopreventive activities. Although there is a large body of evidence supporting the existence of multiple mechanisms for its biological activities (2, 29, 30), details about these mechanisms and the molecular targets of genistein remain to be clarified. Despite the lack of information about how genistein acts at the molecular level, a phase I clinical study in cancer patients has been initiated (31).

The purpose of this present study was to determine whether genistein might affect the expression of the MDM2 oncoprotein, and, if so, whether this effect has biological consequences on the antitumor activities of genistein. We have generated at least five novel results. First, genistein down-regulates MDM2 expression at both the transcriptional and posttranslational levels, independent of p53, in both human cancer and primary cells. At the transcriptional level, the transcription factor NFAT binding site in the MDM2 promoter is important; at the posttranslational level, the genistein-induced MDM2 ubiquitination plays a role. Second, the down-regulation of MDM2 by genistein apparently does not require tyrosine kinase activity. Third, the inhibition of MDM2 by genistein is essential for its antitumor activities, including apoptosis and cell cycle arrest. Fourth, genistein up-regulates the tumor suppressor p21\(^{Waf1/CIP1}\), independent of p53, an effect that may be associated with the inhibition of MDM2. Fifth, genistein has antitumor effects and activities inhibiting MDM2 expression in vivo.

Human MDM2 expression is transcriptionally activated by p53, and there are evolutionarily conserved p53 response elements in its promoter (32). A number of functional, p53-independent response elements in the MDM2 promoter are present, including a thyroid response element and a combination 5’ ETS binding site and composite AP1-ETS site (33). Our observations that genistein decreases MDM2 mRNA levels in cells without functional p53 expression [i.e., PC3 cells (p53\(^{null}\)), HCT116 cells (p53\(^{-/-}\)), and MCF-7 cells (p53\(^{-/-}\))] supports the p53-independent transcriptional control of MDM2 and indicates that the effects of genistein are p53 independent. By luciferase assays, we identified the region of the MDM2 promoter that was responsive to genistein (Luc 03; −132 to +33), offering clues to the mechanisms of genistein-induced decreases in MDM2. For example, the estrogen receptor is recruited to this element to activate the MDM2 promoter (34), and genistein can function as an estrogen antagonist. However, the inhibition of both MDM2 mRNA and promoter activity in HCT116 and PC3 cells does not support antagonism of the estrogen response element.
receptor as the mediator of this effect. In contrast, mutation of the NFAT binding site in the MDM2 promoter eliminates the inhibitory effects of genistein.

NFAT proteins are a family of transcription factors originally identified in T cells as the activators of cytokine gene expression (35). Recently, it has become apparent that NFAT is involved in the regulation of growth and development of cells in a variety of tissues, not only of the immune system (35). The involvement of NFAT proteins in carcinogenesis is now recognized. As shown in vitro, the constitutive mutant NFATc1 transforms 3T3-L1 fibroblasts (36), and NFAT1 and NFAT5 promote tumor invasion (37). NFAT is also involved in the carcinogenic effects of nickel.
compounds (38). The NFATc2 gene is amplified in human pancreatic cancer cell lines and tissue specimens (39). Our data provide evidence that NFAT is involved in the p53-independent up-regulation of MDM2 transcription, which might be one of the mechanisms whereby NFAT proteins promote carcinogenesis. Considering the facts that MDM2 is still expressed or even overexpressed in human cancers lacking functional p53 and the prognosis for patients with cancers having both loss of p53 and MDM2 overexpression is worse than for patients whose cancers have either abnormality alone (40), knowledge about the regulation of MDM2 through other transcription factors, including NFATs, is important for elucidation of the carcinogenesis process.

The posttranslational regulation of the MDM2 protein is complicated. A RING finger domain located in the COOH terminus has ubiquitin E3 ligase function and facilitates the ubiquitination of p53 and MDM2 itself, which consequently leads to proteasome-mediated degradation (41). Because MDM2 facilitates its own ubiquitination, there must be mechanisms decreasing this activity to ensure that MDM2 has sufficient stability to access its targets. Several cellular proteins such as p14Arf, p300, and MDMX interact with the MDM2 protein and affect its E3 ligase function and thus protein stability (42). Posttranslational modifications, including phosphorylation by protein kinases and sumoylation, also control the balance between the autoubiquitination and substrate ubiquitination of MDM2 (28, 43). Based on our observations, genistein shifts the MDM2 E3 ligase activity to autoubiquitination. The RING finger domain of MDM2 may be involved in the switch from substrate to autoubiquitination, as mutation of this domain at least partially reverses the effects of genistein. In accordance with our data, an MDM2 construct with a heterologous RING finger can catalyze its own ubiquitination but not that of p53 (41). This observation has important clinical relevance because MDM2 is up-regulated after DNA damage to limit the extent of p53 activation and thus the effects of cytotoxic therapies. Moreover, the up-regulation of MDM2 results in a variety of other effects due to its p53-independent activities (24). Genistein promotes the self-destabilization of MDM2, providing a rationale for the combination of genistein with DNA-damaging agents to treat human cancers.

Based on the capacity of genistein to inhibit tyrosine kinase activity and the fact that MDM2 is up-regulated by the ras/MEK/MAPK pathway, we hypothesized that the genistein-induced down-regulation of MDM2 was through a tyrosine kinase pathway.

Figure 7. MDM2 expression level relative to the response of PC3 cells to genistein. PC3 cells with stable overexpression (OE) of MDM2 or corresponding empty vector were treated with various concentrations of genistein for 24 hours followed by Western blot analysis (A), apoptosis assay (B), cell proliferation (BrdUrd in corporation) assay (C), or clonogenic assay (D). A, genistein-induced p21 elevation was reversed by MDM2 overexpression. B, genistein-induced apoptosis in PC3 cells was inhibited by MDM2 overexpression. C, in the BrdUrd assay, MDM2-overexpressing cells were less sensitive to the antiproliferative effects of genistein. D1 and D2, clonogenic assay was used to elucidate the possible differences in long-term effects of genistein between parental and MDM2-overexpressing cell lines. After exposure to genistein at various concentrations for 24 hours, cells were cultured for an additional 14 days. At the end of the experiments, cell colonies were fixed, stained, and counted. Representative colonies (D1). Quantitative data are means of duplicate assays; bars, ±SD. In vivo antitumor activity of genistein administered alone or in combination with gemcitabine (E1) in nude mice bearing PC3 xenografts and the protein expression profile of xenografts (E2). Genistein (5 mg/kg/d) treatments were initiated on day 0, 5 days/wk for 4 weeks. Gemcitabine (160 mg/kg) was given at days 11, 18, and 25 by i.p. At the end of the treatment, tumor xenografts were removed and proteins of tumor homogenates were analyzed by Western blotting.
Nevertheless, we observed that EGF, an activator of tyrosine kinases, does not reverse the inhibition of MDM2 by genistein. Still, the possibility that genistein may down-regulate MDM2 through other tyrosine kinase pathways not associated with EGF was not ruled out. Pretreatment with another tyrosine kinase inhibitor, lavendustin, did not affect the down-regulation of MDM2, showing that the down-regulation is not likely to be due to tyrosine kinase inhibition. Further studies are needed, including examination of other isoflavones with structures similar to genistein, to determine if they may also have an effect on MDM2 expression.

The MDM2 oncogene has the capacity to transform cells in culture and is overexpressed in many human malignancies; indeed, high MDM2 levels are associated with poor prognosis and resistance to DNA-damaging agents (19, 44, 45). MDM2 has been suggested as a drug target for human cancer therapy, regardless of the p53 status of the cancer (19–24). In this study, we found that MDM2 is down-regulated by genistein in vitro and in vivo, which may have an important role in its chemopreventive and chemotherapeutic activities. We found that the concentration-and time-dependent down-regulation of MDM2 by genistein was accompanied by induction of apoptosis, inhibition of cell proliferation, and cell cycle arrest at G2-M in human breast, prostate, and colon cancer cell lines, regardless of their p53 status. Overexpression of MDM2 in PC3 cells at least partially impaired the response of tumor cells to the genistein treatment. Although the capacity of genistein to induce apoptosis and G2 arrest has been well documented, the possible mediators of these effects remain unclear (46, 47). More importantly, the in vitro genistein activity was recapitulated in a PC3 xenograft model, and genistein also has in vivo chemosensitization effects on gemcitabine treatment. These observations provide strong support for the use of genistein as an antitumor agent and chemosensitizer for human cancer treatment. Our in vivo data also show that MDM2 is a novel and effective target for cancer therapy, as observed in our other studies using MDM2 antisense inhibitors (20–24).

Our observations suggest that the antitumor activity of genistein is, at least in part, associated with its MDM2 inhibitory effects. Moreover, we also observed that genistein prolonged the half-life of the p21Waf1/CIP1 protein, independent of p53. This was accompanied by MDM2 inhibition, suggesting that the increase in the p21 half-life may be a downstream effect of the p53-independent decrease in MDM2 induced by genistein. To our knowledge, this is the first report showing that p21Waf1/CIP1 protein stability is affected by genistein, although it has been previously reported that genistein increases p21Waf1/CIP1 mRNA (47). In our previous studies (21–24), we found that the p21Waf1/CIP1 protein was a direct target of MDM2 for proapoptotic degradation, independent of p53. We report in the current study that overexpression of MDM2 overcomes the effects of genistein on p21Waf1/CIP1 activation. Because p21Waf1/CIP1 is involved in the genistein-induced apoptosis and G2 arrest in tumor cells (48), and p21Waf1/CIP1 protein is stabilized by genistein, it might be a mediator of the antitumor effects of genistein. In addition, the p53 independence of these effects is clinically relevant because >50% of human cancers, especially advanced stage cancers, have p53 dysfunction (19).

In conclusion, our observations have significance for cancer biology, prevention, and treatment. The present study provides insight into MDM2 regulation in the absence of p53 and provides evidence supporting a previously unrecognized mechanism of action for genistein: direct, p53-independent, down-regulation of the MDM2 oncogene. Considering the numerous activities of MDM2 in cancer growth and progression, as well as in cancer therapy, we speculate that genistein can be used as a chemopreventive and therapeutic agent, alone or in combination with other conventional agents. Continuing research on the p53-independent regulation of MDM2 may also be instrumental in elucidating the process of cancer initiation and progression.

Acknowledgments

Received 4/13/2005; revised 7/7/2005; accepted 7/14/2005.

Grant support: NIH/National Cancer Institute grants R01CA 80968 and R01 CA112029 (R. Zhang), Department of Defense Prostate Cancer Research Program grant number W81XWH-04-1-0845 (Z. Zhang), National Cancer Institute/University of Alabama at Birmingham Comprehensive Cancer Center Junior Faculty Development Grant (H. Wang), and Comprehensive Cancer Center for Cancer Pharmacology Laboratory (H. Wang).

Due to the large size of publication of this article were deferred in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. G. Prasad for excellent technical assistance and E. Rayburn for assistance in preparation of this article.

References


Genistein, a Dietary Isoflavone, Down-Regulates the MDM2 Oncogene at Both Transcriptional and Posttranslational Levels

Mao Li, Zhuo Zhang, Donald L. Hill, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/18/8200

Cited articles
This article cites 44 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/18/8200.full#ref-list-1

Citing articles
This article has been cited by 15 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/65/18/8200.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.